Clinical Trial Update: Neoadjuvant Dupilumab in Men With Localized High-Risk Prostate Cancer [Phase 2]

View source ↗

Summary

Phase 2 neoadjuvant trial of dupilumab in men with localized high-risk prostate cancer was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Dupilumab (dupilumab)

Snippet

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Conditions: Prostate Cancer | Phase 2 | Status: TERMINATED | Results posted: 2021-10-15